IDEAYA Biosciences
IDYA
36.26
-0.37
-1.01%
IDEAYA Biosciences
US · IDYA
#2357 by market cap
Listed 2019
36.26
-0.37
-1.01%
Live - 5344 symbols - heartbeat 66s ago
· 2026-10-08 08:24
Pre-market
37.50
+3.42%
After-hours
36.26
0.00%
- Market cap
- 3.50B
- P/E (TTM)i
- -18.89
- P/Bi
- 2.92
- EPSi
- -1.28
- Div yieldi
- 0.00%
- 52W posi
- 61%
Reader sentiment
Are you bullish or bearish on IDYA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.1 percentage points.
Institutional ownership
- Held by institutions
- 107.17% -0.11pp
- Institutions
- 342 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund79.21%
Hedge Fund19.82%
Public Company3.87%
VC/PE Fund2.41%
Individual/Insider0.88%
Government Pension Fund0.87%
Insurance Company0.49%
Private Company0.40%
Top holders as of 2026-06-30
FMR
14.62% · 14.10M sh
BlackRock
9.22% · 8.89M sh
Janus Henderson Group plc
8.89% · 8.58M sh
Capital Research
5.54% · 5.34M sh
Baker Bros. Advisors LP
5.19% · 5.01M sh
Vanguard Capital Management, LLC
4.93% · 4.75M sh
State Street Global Advisors
4.71% · 4.55M sh
Logos Global Management, L.P.
3.11% · 3.00M sh
Adage Capital Management, L.P.
2.81% · 2.72M sh
Deerfield Management Company, L.P.
2.81% · 2.71M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 43 buys · 5 sells
| Name | Role | Stake |
|---|---|---|
| Yujiro Hata | Chief Executive Officer | 0.72% |
| Jason Throne | Chief Legal Officer & Company Secretary | 0.07% |
| Jeffrey Stein | Independent Director | 0.06% |
| Andres Briseno | Principal Accounting Officer, Senior VP and Head of Finance & Investor Relations | 0.03% |
| Terry Rosen | Independent Chairperson | 0.01% |
| Douglas Snyder | General Counsel | 0.00% |
| Wendy Yarno | Independent Director | -- |
| Scott William Morrison | Independent Director | -- |
| Catherine Mackey | Independent Director | -- |
| Darrin Beaupre | Chief Medical Officer | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-06 | Andres Briseno | Principal Accounting Officer, Senior VP and Head of Finance & Investor Relations | Derivative Exercise and Sale | -9,550 | $12.86–40.01 |
| 2026-06-15 | Wendy Yarno | Independent Director | Other Derivative Acquisition | +20,000 | $30.57 |
| 2026-06-15 | Jeffrey Stein | Independent Director | Other Derivative Acquisition | +20,000 | $30.57 |
| 2026-06-15 | Scott William Morrison | Independent Director | Other Derivative Acquisition | +20,000 | $30.57 |
| 2026-06-15 | Catherine Mackey | Independent Director | Other Derivative Acquisition | +20,000 | $30.57 |
| 2026-06-15 | Terry Rosen | Independent Chairperson | Other Derivative Acquisition | +20,000 | $30.57 |
| 2026-06-15 | Malcolm Hampton | Independent Director | Other Derivative Acquisition | +20,000 | $30.57 |
| 2026-03-01 | Jeffrey Stein | Independent Director | Open Market Acquisition | +50,000 | $32.96 |
| 2026-01-29 | Yujiro Hata | Chief Executive Officer | Other Derivative Acquisition | +600,000 | $32.19 |
| 2026-01-29 | Douglas Snyder | General Counsel | Other Derivative Acquisition | +130,000 | $32.19 |
| 2026-01-29 | Darrin Beaupre | Chief Medical Officer | Other Derivative Acquisition | +175,000 | $32.19 |
| 2026-01-29 | Andres Briseno | Principal Accounting Officer, Senior VP and Head of Finance & Investor Relations | Other Derivative Acquisition | +80,000 | $32.19 |
| 2026-01-29 | Michael White | Chief Scientific Officer | Other Derivative Acquisition | +190,000 | $32.19 |
| 2026-01-29 | Stuart Dorman | Chief Commercial Officer | Other Derivative Acquisition | +155,000 | $32.19 |
| 2026-01-29 | Joshua Bleharski | Chief Financial Officer | Other Derivative Acquisition | +170,000 | $32.19 |
| 2025-11-27 | Douglas Snyder | General Counsel | Other Acquisition | +2,080 | $16.91 |
| 2025-11-27 | Andres Briseno | Principal Accounting Officer, Senior VP and Head of Finance & Investor Relations | Other Acquisition | +1,935 | $16.91–23.26 |
| 2025-06-26 | Joshua Bleharski | Chief Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2025-06-23 | Wendy Yarno | Independent Director | Other Derivative Acquisition | +20,000 | $21.78 |
| 2025-06-23 | Jeffrey Stein | Independent Director | Other Derivative Acquisition | +20,000 | $21.78 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:24:42 · For reference only, not investment advice and not tailored to your situation.